Program
mazdutide
Also written as “IBI362”, “LY3305677” and “Mazdutide”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Overweight · Fatty Liver · Alcoholism, led by 2 companies.
Drug pageMazdutide: every studyAll 44 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologicsits history only | 208 open or running | phase 3since Oct 19, 2022 | Jun 5, 2020 | Dec 31, 2026phase 3 · NCT06884293 |
| Eli Lilly | 71 open or running | phase 2since Nov 6, 2023 | Nov 21, 2016 | Sep 2027phase 2 · NCT06143956 |
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseInnovent licensed it from Lilly, for China.Announced Aug 21, 2019 · Source: Innovent (release), Aug 21, 2019
History and studies of Eli Lilly only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Nov 21, 2016First study: phase 1 study in HealthyFirst studyNCT02972645 · 66 enrolled · United Kingdom
- Oct 26, 2017Phase 1 study in HealthyNCT03325387 · 56 enrolled · United Kingdom
- Apr 24, 2019Phase 1 study in Diabetes Mellitus, Type 2NCT03928379 · 24 enrolled · Germany
- Aug 21, 2019Innovent licensed it from LillyLicenseChina · announced · Innovent (release)
- Jan 25, 2022Named mazdutideINNProposed as its International Nonproprietary Name in WHO's List 126 · before, IBI362, LY3305677
- Nov 15, 2022Phase 1 study in OverweightNCT05623839 · 32 enrolled · United States
- Nov 6, 20232 phase 2 studies in ObesityNCT06143956, NCT06124807
- Feb 5, 2025Phase 2 study in AlcoholismNCT06817356 · 308 enrolled · United States
Ahead
- Sep 2027Primary completion: phase 2 study in ObesityNCT06143956
TargetBeta
“Mazdutide is a synthetic peptide analog of mammalian oxyntomodulin and a once-weekly dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), under development for the treatment of obesity and type 2 diabetes (T2D).”study text, by rule · the study
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| zenagamtide | Novo Nordisk | phase 3 | 36 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| brenipatide | Eli Lilly | phase 3 | 19 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
Studies
All 7 Eli Lilly leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06817356Alcoholism · United States | 2 | Completed | Mar 19, 2026 | 308 |
| NCT06143956Obesity · United States, Argentina | 2 | Recruiting | Sep 2027 | 1,481 |
| NCT06124807Obesity · United States | 2 | Completed | Jan 22, 2025 | 179 |
| NCT05623839Overweight · United States | 1 | Completed | Jun 27, 2023 | 32 |
| NCT03928379Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Jul 8, 2021 | 24 |
| NCT03325387Healthy · United Kingdom | 1 | Completed | Aug 3, 2018 | 56 |
| NCT02972645Healthy · United Kingdom | 1 | Completed | Jul 14, 2017 | 66 |
How it is read
Names in the registry
- “IBI362”, 19 entries
- “LY3305677”, 5 entries
- “Mazdutide”, 2 entries
- “IBI362 liquid formulation”, 1 entry
- “IBI362 lyophilized powder”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 13 studies
- Diabetes Mellitus, Type 2, 6 studies
- Overweight, 2 studies
- Fatty Liver, 1 study
- Alcoholism, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.